Therapeutic Antibodies – Products

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.

Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.

Binding affinity is a significant factor to consider. However, relying solely on affinity can be problematic, as the highest affinity mAbs may not exhibit optimal activity. To ensure the best lead candidates, it is crucial to consider factors like specificity, selectivity and biological relevance.

Lonza, announced the extension of a collaboration with a major biopharmaceutical partner for the commercial-scale filling of ADCs.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Learn more!

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development. Our BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.

Monoclonal antibody (mAb)–based therapeutics have been very successful in treating various diseases, including cancer. The manufacturing of these therapeutic antibodies is a complex operation with low levels of aggregates being a critical quality attribute of the final product, as this will impact the biological activity.